Monday, April 1, 2013
Buysiders are being drawn to
mid- and small cap biotechs with solid balance sheets and/or near-term
inflection points going into 2Q13, a period that may be relatively quiet for
some of the sector's largest names.
The challenging environment for
illiquid micro-caps seems likely to persist, though investors chasing returns
will inevitably take some fliers on smaller names.